Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Rating of “Buy” from Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $147.50.

A number of equities research analysts recently weighed in on the company. Jefferies Financial Group boosted their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Needham & Company LLC upped their price objective on Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Mizuho raised their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th. Finally, Leerink Partners raised their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd.

Vaxcyte Trading Up 1.5 %

Shares of Vaxcyte stock opened at $113.14 on Friday. The firm’s 50 day moving average is $92.24 and its 200 day moving average is $77.80. The firm has a market capitalization of $12.31 billion, a PE ratio of -26.43 and a beta of 0.97. Vaxcyte has a 1 year low of $44.20 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter in the prior year, the firm posted ($0.70) EPS. As a group, research analysts anticipate that Vaxcyte will post -4.33 earnings per share for the current year.

Insider Buying and Selling at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the transaction, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,479,005.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares of the company’s stock, valued at $10,479,005.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Mikhail Eydelman sold 1,667 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $76.37, for a total transaction of $127,308.79. Following the completion of the transaction, the senior vice president now owns 30,826 shares in the company, valued at approximately $2,354,181.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 78,283 shares of company stock valued at $7,064,138. 3.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its holdings in Vaxcyte by 12.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 481,119 shares of the company’s stock worth $30,214,000 after purchasing an additional 52,005 shares in the last quarter. Vestal Point Capital LP acquired a new stake in shares of Vaxcyte during the 4th quarter worth approximately $32,970,000. Harbor Capital Advisors Inc. increased its stake in shares of Vaxcyte by 392.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock valued at $3,046,000 after acquiring an additional 32,149 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Vaxcyte by 10.5% during the 4th quarter. TD Asset Management Inc now owns 167,036 shares of the company’s stock valued at $10,490,000 after acquiring an additional 15,890 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in Vaxcyte by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock worth $216,966,000 after acquiring an additional 498,359 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.